Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance

Abstract Due to compromised homologous recombination (HR) repair, BRCA1‐ and BRCA2‐mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically BRCA2‐deficient cells, we screened a chemical library containing compounds i...

Full description

Bibliographic Details
Main Authors: Eliana MC Tacconi, Sophie Badie, Giuliana De Gregoriis, Timo Reisländer, Xianning Lai, Manuela Porru, Cecilia Folio, John Moore, Arnaud Kopp, Júlia Baguña Torres, Deborah Sneddon, Marcus Green, Simon Dedic, Jonathan W Lee, Ankita Sati Batra, Oscar M Rueda, Alejandra Bruna, Carlo Leonetti, Carlos Caldas, Bart Cornelissen, Laurent Brino, Anderson Ryan, Annamaria Biroccio, Madalena Tarsounas
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:EMBO Molecular Medicine
Subjects:
alkylating agents
BRCA1
BRCA2
cisplatin
DNA damage responses
Online Access:https://doi.org/10.15252/emmm.201809982

Internet

https://doi.org/10.15252/emmm.201809982

Similar Items